The short answer: A gastroenterology infusion claim can fail in three places that have nothing to do with the clinical decision. The authorization is drug-specific and may not cover the biologic actually administered. The site of care may be steered by the payer to a setting the practice did not plan for. And the J-code units, modifiers or diagnosis specificity can be wrong on an otherwise valid claim. Each failure costs thousands of dollars per encounter, because that is what a single infliximab or vedolizumab infusion is worth. Advantum Health builds prior authorization and medical coding workflows around all three.
Scope note. Payer policies for biologics differ substantially by plan and change frequently. Verify current criteria, preferred products and site-of-care requirements against the specific plan policy before every authorization rather than relying on a prior approval.
Why this matters: the dollars per claim are large and the failures are quiet
Most revenue cycle risk is distributed. A denial here, an underpayment there, aggregated into a rate. Infusion biologics do not work that way. The exposure concentrates into individual encounters worth thousands of dollars each, on a recurring schedule, for patients who will be on therapy for years.
That changes the economics of prevention. In a general medical workflow, a scrubber that catches most errors is adequate. In a gastroenterology infusion workflow, the claims that slip through are the expensive ones, and the practice has usually already purchased and administered the drug. The loss is not deferred revenue. It is inventory.
The authorization is for a drug, not a service
This is the single most common and most expensive misunderstanding. An authorization approves a specific product for a specific patient under specific clinical criteria. It does not approve infusion therapy generally.
The practical consequences follow directly. A patient switched from one biologic to another mid-cycle needs a new authorization, even though nothing about the appointment type changed. A dose escalation or a frequency change can require a new authorization. A biosimilar substitution can invalidate an authorization written for the reference product, and the reverse is also true where a plan operates a biosimilar-first policy.
Payer criteria for these products are detailed and specific. Typical requirements include a confirmed diagnosis documented by endoscopic or clinical assessment, documented failure or intolerance of conventional therapy and often a TNF inhibitor, prescribing by a gastroenterologist, completed tuberculosis and hepatitis B screening and current immunizations. A submission that does not address the plan’s stated criteria point by point invites a denial that then has to be appealed on the same facts that should have been supplied the first time.
The operational fix is a workflow that checks authorization status at every encounter rather than at the start of a therapy course, and that treats any change in drug, dose or frequency as a trigger for reauthorization.
Site of care is now a payer decision
Payers increasingly direct infused biologics away from hospital outpatient departments toward ambulatory infusion centers, physician offices or home infusion. For a gastroenterology practice this cuts both ways depending on where its infusion capacity sits.
A practice with its own infusion suite may benefit from steering policies. A practice whose patients infuse at a hospital outpatient department may find an approved authorization still produces a denial because the site was not approved. Either way, the site of care must be confirmed as part of the authorization rather than assumed from the last course of therapy, and place-of-service coding must match where the drug was actually administered.
The J-code details that sink otherwise clean claims
Units. J-codes are billed in defined units that rarely correspond to a vial or a dose. Unit math on a high-cost biologic is where a single transposition becomes a four-figure variance, in either direction.
JW and JZ modifiers. CMS requires the JW modifier to report discarded drug from single-dose containers and the JZ modifier to attest that there was no discarded amount. Missing either is a predictable edit, and unreported wastage on an expensive biologic is revenue left behind.
Diagnosis specificity. An unspecified code such as K50.90 or K51.90 will often clear a clearinghouse edit and then fail medical necessity review at adjudication. Scrubbers check syntax. Payers check specificity.
Administration code selection. Infusion administration coding follows a hierarchy, and payer positions vary on which administration codes are acceptable for a given product. Some contractors do not accept chemotherapy administration codes for certain biologics. Confirm against the contractor and plan rather than the manufacturer’s general guidance.
Eligibility at every encounter. Specialty drug coverage changes more often than patients report it. A verification gap of a single month on a recurring infusion schedule can expose the practice to a full write-off.
Do not expect the 2026 prior authorization rule to solve this
The federal interoperability and prior authorization rule finalized for payers brings real improvements to authorization timelines and transparency. It is worth knowing exactly what it does not cover.
The CMS Interoperability and Prior Authorization final rule applies to items and services. Drugs are excluded. That means the workflow generating the most authorization burden and the most revenue risk in a gastroenterology infusion practice sits outside the scope of the regulatory relief arriving for everything else. Practices planning on the rule to reduce infusion authorization work should plan differently.
A checklist for practice administrators
- Verify authorization at every infusion encounter, not only at the start of a therapy course.
- Treat any change in drug, dose, frequency or biosimilar status as a reauthorization trigger.
- Confirm the approved site of care with the authorization and match place-of-service coding to where the drug was administered.
- Build the authorization submission against the plan’s published clinical policy, addressing each criterion explicitly.
- Capture and retain screening and immunization documentation before the first infusion, not at appeal.
- Audit J-code unit calculations for every product on your formulary.
- Confirm JW and JZ modifier logic is applied consistently and that wastage is documented.
- Replace unspecified diagnosis codes with the most specific code the documentation supports.
- Run eligibility before every scheduled infusion, not only at intake.
- Route recurring infusion denials into root-cause review rather than rework.
Build the workflow around the drug
A generic claim scrubber will pass a gastroenterology infusion claim with an authorization that covers a different biologic, because the claim is technically valid. It is just not payable. That gap is the whole problem.
Advantum Health builds gastroenterology revenue cycle work around how these products are actually paid: drug-specific authorization, site-of-care confirmation, unit and modifier accuracy and diagnosis specificity that survives medical necessity review. When a denial still happens, it goes into denial management with root-cause analysis rather than back into the queue.
Start with a coding audit of your last quarter of infusion claims. The unit errors and modifier gaps that pay a little less than they should are the ones you will not find in a denial report.